
Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsPrilenia Reports Functional and Survival Signals for Pridopidine in ALSPrilenia Therapeutics and Ferrer reported exploratory functional, respiratory, and survival findings associated with pridopidine in 36 participants with early ALS.Fact-Checked
Clinical TrialsUroGen’s Five-Year Data Support Durable JELMYTO ResponsesUroGen Pharma’s five-year OLYMPUS follow-up showed a median response duration of 47.8 months among 41 complete responders treated with JELMYTO.Fact-Checked
Clinical TrialsRetatrutide Delivers 20.9% Mean Weight Loss Against SemaglutideEli Lilly reports Phase 3 TRANSCEND-T2D-2 results showing 19.5% and 20.9% mean weight loss with retatrutide 9 mg and 12 mg, respectively, versus 9.4% with semaglutide 2 mg…Fact-Checked
Clinical TrialsLynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid ArthritisLynk Pharmaceuticals reports sustained zemprocitinib responses through week 76 in Phase III COURAGE-RA, with efficacy and long-term safety limitations. Written…Fact-Checked
Clinical TrialsAmgen Reports Phase 3 Success for Dazodalibep in Sjögren’s DiseaseAmgen’s Phase 3 OASIZ-301 trial showed that dazodalibep significantly reduced systemic disease activity in Sjögren’s disease at Week 48 with both four-weekly and 12-weekly dosing.Fact-Checked
Clinical TrialsGrünenthal Reports Sustained Pain Reduction With QutenzaGrünenthal reported mixed Phase III results for Qutenza in post-surgical neuropathic pain. The RISE trial met its average pain-reduction endpoint over weeks 2–12, while the Week 12 endpoint…Fact-Checked
Clinical TrialsVanda Reports Positive Results for Tradipitant in GLP-1 VomitingVanda Pharmaceuticals’ Phase 3 Study 3601 found that tradipitant reduced vomiting following a single 1 mg semaglutide dose, with vomiting reported in 43.0% of participants versus 58.5% with…Fact-Checked
Clinical TrialsBeam’s BEAM-301 Shows Early Metabolic Benefits in GSDIaBeam Therapeutics’ BEAM-301 showed early evidence of improved glucose regulation in patients with glycogen storage disease type Ia (GSDIa).Fact-Checked
Clinical TrialsArtiva Ends AlloNK Development After Durability Shortfall and Two Fatal EventsArtiva Biotherapeutics has discontinued AlloNK development after updated findings showed insufficient response durability despite continued B-cell depletion and clinical activity.Fact-Checked
Clinical TrialsPfizer Reports Positive PFS Results for ELREXFIO in RRMM TrialPfizer reports that ELREXFIO (elranatamab) met the primary progression-free survival endpoint in the Phase 3 MagnetisMM-32 trial in relapsed or refractory multiple myeloma.Fact-Checked
Clinical TrialsOncolytics Reports Promising Survival Data With Pelareorep CombinationOncolytics Biotech reported an approximately 15-month median duration of response with pelareorep plus atezolizumab in previously treated squamous cell anal cancer.Fact-Checked
Clinical TrialsTonix Reports Positive FIQR Results for TONMYA in Fibromyalgia TrialsTonix Pharmaceuticals reports Phase 3 findings showing greater improvements in patient-reported fibromyalgia symptoms and function with TONMYA versus placebo in the RELIEF and RESILIENT trials.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.